Keytruda

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

In its new NSCLC setting, Libtayo will take on Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab). ... Keytruda has become the new standard-of-care treatment for newly-diagnosed advanced NSCLC, after first winning approval in

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

NMIBC). A number of immunotherapies are approved for bladder cancer, including Merck &Co/MSD’s Keytruda (pembrolizumab) which became the first checkpoint inhibitor to be approved in the US for NMIBC

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

The overall response rate (ORR) for Keytruda plus Lenvima-treated patients was 71% compared to 36.1% in the Sutent group. ... In this trial, Keytruda plus Lenvima demonstrated superior efficacy benefits compared with Sutent.

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

Both Opdivo combinations will compete with Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (axitinib), after the combination treatment received FDA approval in the same ... Topline results from the

Merck’s CEO Kenneth Frazier to retire after ten years in the role

Under his leadership, Merck has seen impressive growth for its immunotherapy blockbuster Keytruda (pembrolizumab) and other innovative treatments.

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]